Read PDF Books with PubReader view

• Pharmacoeconomic Review Report: Lumacaftor/Ivacaftor (Orkambi): (Vertex Pharmaceuticals (Canada) Incorporated): Indication: For the treatment of cystic fibrosis in patients 6 years of age and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene [Internet].
  Orkambi is a fixed-dose combination tablet containing 200 mg lumacaftor and 125 mg ivacaftor (LUM/IVA). It is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane regulator (CFTR) gene. This is most common CF-causing mutation worldwide and […]
• Pharmacoeconomic Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet].
  Tapentadol ER (Nucynta Extended-Release) is indicated for the management of patients with pain severe enough to require daily, continuous, long-term opioid treatment, and that is opioid responsive, and for which alternative treatment options are inadequate. Tapentadol ER tablets are available in 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg strengths. The submitted […]
• Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet].
  The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative […]
• Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet].
  The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the symptomatic treatment of lower-limb spasticity in pediatric patients two years of age and older.
• Pharmacoeconomic Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada, Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet].
  AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injections, or 20 U/kg to 30 U/kg for bilateral lower-limb injections per treatment […]
• Pharmacoeconomic Review Report: Riociguat (Adempas) [Internet].
  Riociguat (Adempas) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1), as monotherapy or in combination with endothelin receptor antagonists (ERAs) in adult patients (≥ 18 years of age) with WHO functional class II or III pulmonary hypertension. It is available in […]
• Uroscopy and Urinary Ailments in Medieval Welsh Medical Texts.
  The corpus of late fourtenth-century medieval Welsh medical recipes often attributed to the legendary Physicians of Myddfai includes a number of recipes meant to treat urinary ailments, as well as directions on how to diagnose conditions, and provide prognosis to patients, based on the appearance of their urine. These directions are quite obviously related to […]
• ‘In humanity’s machine’: Prison health and history.
  The pernicious and damaging effects of incarcerating juveniles has long been a topic of concern and controversy for reform groups, policy makers, childcare practitioners and academics; such concerns are doubly compounded where the mental health needs of the confined young person are in question. Yet, while there is a considerable scholarly literature on the history […]
• Oxford Handbook of Philosophy and Disability.
• Continuous Manufacturing for the Modernization of Pharmaceutical Production: Proceedings of a Workshop.
  On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for […]